AR 2015

Filgotinib in Phase 3

FINCH program in RA has started

Read the press release

Welcome to Galapagos

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives. 

Learn more about Galapagos

Novel targets, better treatments

Watch our target discovery animation. 

Read more


Global development filgotinib

Galapagos and Gilead have announced a global partnership to develop and commercialize filgotinib for the treatment of rheumatoid arthritis and other inflammatory diseases.

Read more